Commonwealth Equity Services’s Franklin Genomic Advancements ETF HELX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q3 | – | Sell |
-6,677
| Closed | -$212K | – | 4126 |
|
|
2024
Q2 | $212K | Sell |
6,677
-365
| -5% | -$11.6K | ﹤0.01% | 3592 |
|
|
2024
Q1 | $231K | Hold |
7,042
| – | – | ﹤0.01% | 3506 |
|
|
2023
Q4 | $215K | Sell |
7,042
-915
| -11% | -$27.9K | ﹤0.01% | 3450 |
|
|
2023
Q3 | $225K | Buy |
7,957
+38
| +0.5% | +$1.08K | ﹤0.01% | 3282 |
|
|
2023
Q2 | $239K | Sell |
7,919
-792
| -9% | -$23.9K | ﹤0.01% | 3235 |
|
|
2023
Q1 | $264 | Sell |
8,711
-324
| -4% | -$10 | ﹤0.01% | 3074 |
|
|
2022
Q4 | $272K | Buy |
9,035
+188
| +2% | +$5.66K | ﹤0.01% | 2951 |
|
|
2022
Q3 | $262K | Buy |
8,847
+372
| +4% | +$11K | ﹤0.01% | 2934 |
|
|
2022
Q2 | $271K | Sell |
8,475
-2,143
| -20% | -$68.5K | ﹤0.01% | 2931 |
|
|
2022
Q1 | $392K | Sell |
10,618
-4,382
| -29% | -$162K | ﹤0.01% | 2733 |
|
|
2021
Q4 | $727K | Sell |
15,000
-131
| -0.9% | -$6.35K | ﹤0.01% | 2224 |
|
|
2021
Q3 | $791K | Sell |
15,131
-1,191
| -7% | -$62.3K | ﹤0.01% | 2109 |
|
|
2021
Q2 | $845K | Sell |
16,322
-55
| -0.3% | -$2.85K | ﹤0.01% | 2048 |
|
|
2021
Q1 | $710K | Buy |
16,377
+10,279
| +169% | +$446K | ﹤0.01% | 2062 |
|
|
2020
Q4 | $270K | Buy |
6,098
+178
| +3% | +$7.88K | ﹤0.01% | 2665 |
|
|
2020
Q3 | $207K | Buy |
+5,920
| New | +$207K | ﹤0.01% | 2689 |
|